You are here: Home » News-CM » Companies » News
Business Standard

Glenmark Pharmaceuticals initiates Phase 2b Trial of GBR 830

Capital Market 

A potential treatment for moderate-to-severe atopic dermatitis

announced the initiation of a Phase 2b clinical trial of GBR 830, a novel, for moderate-to-severe The trial's primary endpoint will assess the efficacy of GBR 830, compared to placebo. Secondary and exploratory trial endpoints include additional measures of efficacy, safety and Trial enrollment is expected to begin in June 2018.

In addition to moderate-to-severe atopic dermatitis, Glenmark is evaluating the potential for conducting studies with GBR 830 for the treatment of other where dysregulation of OX40 overexpression is implicated in activity. Preparations for a clinical trial assessing GBR 830 for the treatment of (SLE) are currently underway.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, April 17 2018. 10:50 IST